Pages that link to "Q34273373"
Jump to navigation
Jump to search
The following pages link to B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study (Q34273373):
Displaying 50 items.
- Vaccines: from empirical development to rational design (Q21089599) (← links)
- Antibody-guided vaccine design: identification of protective epitopes (Q26747139) (← links)
- HIV-Host Interactions: Implications for Vaccine Design (Q26765966) (← links)
- Recent update in HIV vaccine development (Q26766628) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- A Blueprint for HIV Vaccine Discovery (Q26829865) (← links)
- A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine (Q26830360) (← links)
- A brief history of the global effort to develop a preventive HIV vaccine (Q26851165) (← links)
- Designing synthetic vaccines for HIV (Q26862617) (← links)
- HIV-1 neutralizing antibodies: understanding nature's pathways (Q27000480) (← links)
- Antibodies in HIV-1 vaccine development and therapy (Q27011574) (← links)
- HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design (Q27022055) (← links)
- A global approach to HIV-1 vaccine development (Q27024614) (← links)
- Virological features associated with the development of broadly neutralizing antibodies to HIV-1 (Q27025177) (← links)
- Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody (Q27644415) (← links)
- Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (Q27644501) (← links)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
- Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design (Q27644634) (← links)
- Broad and potent neutralization of HIV-1 by a gp41-specific human antibody (Q27675131) (← links)
- Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody (Q27675207) (← links)
- Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 (Q27675468) (← links)
- Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 (Q27675879) (← links)
- Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody (Q27677011) (← links)
- Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors (Q27677104) (← links)
- Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains (Q27684503) (← links)
- Progress in HIV-1 vaccine development. (Q27693849) (← links)
- New concepts in HIV-1 vaccine development (Q28067027) (← links)
- High-Throughput Sequencing-Based Immune Repertoire Study during Infectious Disease (Q28068214) (← links)
- Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design (Q28075274) (← links)
- Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (Q28271300) (← links)
- Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies (Q28602877) (← links)
- HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers (Q28647225) (← links)
- A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines (Q30234577) (← links)
- Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem (Q30234773) (← links)
- Computational tools for epitope vaccine design and evaluation (Q30373339) (← links)
- Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design (Q30374314) (← links)
- Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. (Q30382955) (← links)
- Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. (Q30490942) (← links)
- Lessons learned from human HIV vaccine trials (Q33557844) (← links)
- Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy (Q33611645) (← links)
- Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates (Q33612459) (← links)
- Novel directions in HIV-1 vaccines revealed from clinical trials (Q33645528) (← links)
- HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies (Q33753573) (← links)
- Which Antibody Functions are Important for an HIV Vaccine? (Q33772637) (← links)
- A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism (Q33793007) (← links)
- Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (Q33813145) (← links)
- Redemption of autoreactive B cells (Q33835034) (← links)
- The promise and challenge of high-throughput sequencing of the antibody repertoire. (Q33962293) (← links)
- Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination (Q34022578) (← links)
- The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires (Q34101087) (← links)